PwPepwise

Semaglutide

Weight Loss

a.k.a. Ozempic · Wegovy · Rybelsus

GLP-1 receptor agonist

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a medicine that mimics a natural gut hormone released after eating.

§Dosing at a glance

6 protocols · from the research
What it's forDoseHow oftenHowFor how long
Obesity / Weight Management (without type 2 diabetes)2.4 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.68 wks
Type 2 Diabetes (blood-sugar control and lower heart risk)0.5 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.4 yrs
Obesity with Type 2 Diabetes2.4 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.68 wks
heart failure2.4 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.52 wks
fatty liver disease2.4 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.72 wks
Knee Osteoarthritis2.4 mgOnce weeklySubcutaneousInjected just under the skin, into the fat layer.68 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a medicine that mimics a natural gut hormone released after eating. By activating GLP-1 receptors in the brain, pancreas, and other organs, it reduces appetite, slows stomach emptying, and improves the body's ability to regulate blood sugar. Originally developed for type 2 diabetes, semaglutide has demonstrated benefits across a remarkably broad range of conditions.

In adults with obesity, once-weekly injectable semaglutide 2.4 mg reduces body weight by approximately 15% on average — a magnitude previously associated only with bariatric surgery1,17. It also reduces the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in people with obesity but without diabetes2, and by 26% in people with type 2 diabetes4. In patients with chronic kidney disease and type 2 diabetes, semaglutide reduces the risk of serious kidney disease events by 24%3. Further evidence shows meaningful benefits in heart failure with preserved ejection fraction6,9,12, metabolic liver disease10, and knee osteoarthritis pain13. Both injectable and oral formulations are available, with the oral 50 mg daily formulation achieving weight loss comparable to the injectable version11.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Semaglutide is a synthetic, acylated analogue of human glucagon-like peptide-1 (GLP-1), a 30-amino acid incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Its peptide backbone shares 94% sequence homology with native GLP-1(7-37), with two key structural modifications: a substitution of lysine for arginine at position 34 (preventing DPP-4 cleavage) and attachment of a C18 fatty diacid chain via a linker at position 26, enabling reversible albumin binding. These modifications dramatically extend the plasma half-life to approximately 165–184 hours (approximately 7 days), supporting once-weekly dosing for the subcutaneous formulation4,1.

Semaglutide acts as a full agonist at the GLP-1 receptor (GLP-1R), a class B G-protein coupled receptor expressed in pancreatic beta cells, hypothalamic appetite-regulating nuclei (arcuate, paraventricular, and dorsomedial nuclei), brainstem (nucleus of the solitary tract), cardiac myocytes, vascular endothelium, renal tubular cells, hepatocytes, and synovial tissue. Upon GLP-1R activation, the canonical signaling cascade involves Gαs-mediated adenylyl cyclase stimulation, cyclic AMP accumulation, and downstream PKA/EPAC activation. In pancreatic beta cells, this enhances glucose-dependent insulin secretion and suppresses glucagon release from alpha cells, providing glycemic benefit without intrinsic hypoglycemia risk4,8. In hypothalamic and brainstem circuits, GLP-1R activation reduces appetite and caloric intake by modulating anorexigenic neuropeptide expression and increasing satiety signaling — the primary driver of the 14–16% mean weight loss observed in obesity trials1,11,17.

Beyond glycemic and weight effects, GLP-1R agonism exerts direct cardioprotective, nephroprotective, and anti-inflammatory actions. Semaglutide reduces systemic C-reactive protein by up to 43.5% in HFpEF patients6, suggesting anti-inflammatory effects that may be partially independent of weight loss. In the kidney, GLP-1R activation reduces intraglomerular pressure, attenuates oxidative stress, and decreases tubular inflammation, contributing to the 24% reduction in major kidney disease events observed in CKD patients with type 2 diabetes3. The 20% cardiovascular risk reduction observed in non-diabetic obese patients2 — where glycemic improvement is absent — indicates that vascular protection mechanisms include weight-loss-mediated improvements in blood pressure, dyslipidemia, and inflammation, as well as potential direct endothelial GLP-1R effects. The analgesic and functional benefits observed in knee osteoarthritis13 suggest additional GLP-1R expression in joint tissue or indirect anti-inflammatory signaling pathways that are an active area of mechanistic investigation.

For the oral formulation, bioavailability of GLP-1 peptides is inherently low due to gastric proteolysis and poor mucosal permeability. Oral semaglutide co-formulates the peptide with sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC), an absorption enhancer that transiently elevates gastric pH locally and facilitates transcellular absorption across gastric epithelium. The oral 14 mg daily dose achieves cardiovascular efficacy in type 2 diabetes15,16, while the higher 50 mg oral formulation delivers weight loss comparable to the 2.4 mg subcutaneous dose11, reflecting the nonlinear bioavailability-dose relationship of this delivery system.

§04Evidence & efficacy

Evidence base
390Studies
207Human
6Animal

Semaglutide demonstrates strong, replicated efficacy across multiple distinct therapeutic indications, each supported by adequately powered, placebo-controlled RCTs.

Obesity and Weight Management:
Once-weekly subcutaneous semaglutide 2.4 mg reduces mean body weight by approximately 14.9–16.0% versus 2.4–5.7% for placebo over 68 weeks in adults without type 2 diabetes1,17. In adults with type 2 diabetes, the same dose achieves 9.6% mean weight reduction versus 3.4% for placebo8, demonstrating that diabetes attenuates, but does not eliminate, the weight loss response. Weight loss is not sustained upon discontinuation — participants who switched to placebo after a 20-week run-in regained approximately 6.9% body weight within 48 weeks, underscoring the need for continuous treatment7. Over 4 years of follow-up in the SELECT trial, semaglutide maintained a 10.2% mean weight reduction versus 1.5% for placebo14. Oral semaglutide 50 mg once daily achieves comparable weight loss to the injectable formulation, with a mean reduction of 15.1% versus 2.4% for placebo at 68 weeks11. Semaglutide 2.4 mg produces approximately 2.5-fold greater weight loss than liraglutide 3.0 mg daily (-15.8% vs -6.4%)18.

Cardiovascular Risk Reduction:
In patients with type 2 diabetes, semaglutide (0.5–1.0 mg weekly) reduces the primary MACE composite (cardiovascular death, nonfatal MI, nonfatal stroke) with a 26% relative risk reduction (HR 0.74)4. In patients with obesity but without diabetes, semaglutide 2.4 mg weekly reduces MACE by 20% (HR 0.80) over a mean of 34.2 months2. Oral semaglutide (14 mg daily) reduces MACE by 14% (HR 0.86) in high-risk type 2 diabetes patients15.

Chronic Kidney Disease:
In patients with type 2 diabetes and CKD, semaglutide 1.0 mg weekly reduces the composite kidney outcome (kidney failure, ≥50% eGFR reduction, or kidney/cardiovascular death) by 24% (HR 0.76), slows eGFR decline by 1.16 ml/min/1.73m² per year, and reduces all-cause mortality by 20%3. The trial was stopped early at a prespecified interim analysis due to overwhelming efficacy.

Heart Failure with Preserved Ejection Fraction:
Semaglutide 2.4 mg weekly significantly improves KCCQ clinical summary scores, body weight, 6-minute walk distance, and the hierarchical composite endpoint in both non-diabetic (win ratio 1.72)6 and diabetic HFpEF populations (win ratio 1.58)9. Pooled analysis confirms consistent effects across both populations (KCCQ-CSS improvement +7.5 points; weight reduction -8.4%; 6MWD +17.1 m; hierarchical composite win ratio 1.65)12.

Metabolic Dysfunction-Associated Steatohepatitis (MASH):
Semaglutide 2.4 mg weekly achieves steatohepatitis resolution without fibrosis worsening in 62.9% of patients versus 34.3% with placebo, and reduces liver fibrosis without steatohepatitis worsening in 36.8% versus 22.4%10.

Knee Osteoarthritis:
Semaglutide 2.4 mg weekly reduces WOMAC pain scores by 41.7 points versus 27.5 points with placebo, with the differential in pain reduction proportionally exceeding the differential in weight loss13.

Glycemic Control (Type 2 Diabetes):
Semaglutide 1.0 mg weekly reduces HbA1c by 1.8 percentage points versus 1.4 for dulaglutide 1.5 mg19. Tirzepatide at all doses achieves superior HbA1c reductions compared to semaglutide 1.0 mg, with differences of -0.15 to -0.45 percentage points5.

§05Safety

Semaglutide has an extensively characterized safety profile across hundreds of clinical trials and tens of thousands of patient-years of exposure. The most consistently observed adverse effects are gastrointestinal in nature — primarily nausea, diarrhea, and vomiting — which are dose-dependent, typically mild-to-moderate in severity, and tend to subside over time with the gradual dose-escalation protocol1,7,8. In the STEP 1 obesity trial, gastrointestinal events led to treatment discontinuation in 4.5% of semaglutide participants versus 0.8% on placebo1. In the STEP 3 trial combining semaglutide with intensive behavioral therapy, GI adverse events occurred in 82.8% of the semaglutide group compared to 63.2% on placebo, though treatment discontinuation due to GI events was only 3.4%17. Oral semaglutide 50 mg is associated with GI adverse events in approximately 80% of participants, though these are mostly mild-to-moderate11.

In the SUSTAIN 6 cardiovascular outcomes trial in type 2 diabetes, a significantly increased risk of retinopathy complications was observed (HR 1.76, 95% CI 1.11–2.78)4 — a clinically important safety signal that has been attributed to rapid glucose-lowering in patients with pre-existing retinopathy. In the SELECT cardiovascular outcomes trial (obesity without diabetes), permanent discontinuation of the trial product occurred roughly twice as often in the semaglutide arm as placebo (16.6% vs 8.2%)2, reflecting a meaningful tolerability burden in a long-duration trial. Treatment discontinuation rates were inversely correlated with BMI class in the SELECT weight loss analysis, suggesting tolerability challenges may be more pronounced in patients with lower baseline obesity14.

A consistently reassuring finding across multiple large RCTs is that serious adverse event rates are lower in semaglutide-treated participants than in placebo recipients — observed in HFpEF trials6,9,12, the CKD outcomes trial3, the STEP 4 withdrawal trial7, and the SELECT long-term weight loss analysis14. Gastrointestinal adverse event rates are similar between semaglutide and liraglutide, but overall discontinuation rates are substantially lower with semaglutide (13.5% vs 27.6%)18. In the SURPASS-2 head-to-head trial, serious adverse events were more frequent with tirzepatide (5–7%) compared to semaglutide (3%)5, favorably contextualizing semaglutide's tolerability.

§06History

Semaglutide was developed by Novo Nordisk as part of a systematic research program into long-acting GLP-1 receptor agonists following the clinical success of exenatide (2005) and liraglutide (2010). The foundational insight was that extending the half-life of GLP-1 analogues through fatty acid acylation — pioneered with liraglutide — could be further optimized to enable once-weekly dosing. Semaglutide's unique structural modifications (arginine substitution at position 34 and C18 fatty diacid acylation at position 26 via a hydrophilic linker) produced a half-life of approximately 7 days, enabling the once-weekly subcutaneous formulation.

Phase 2 dose-ranging studies established a clear dose-response relationship for weight loss and glycemic control, with semaglutide doses ≥0.2 mg significantly outperforming liraglutide 3.0 mg — foreshadowing later phase 3 results20. The SUSTAIN clinical trial program (2016–2018) established glycemic efficacy and cardiovascular safety, with SUSTAIN 6 (2016) demonstrating landmark cardiovascular superiority in type 2 diabetes while also identifying the retinopathy safety signal4. Subcutaneous semaglutide 0.5/1.0 mg received FDA approval for type 2 diabetes in December 2017.

The PIONEER program demonstrated feasibility of the oral formulation, with PIONEER 6 (2019) establishing cardiovascular noninferiority16. The STEP program (2021) established semaglutide 2.4 mg as a transformative obesity treatment1,7,8,17, leading to FDA approval for chronic weight management in June 2021. The SELECT trial (2023) expanded cardiovascular indications to non-diabetic obesity2, the FLOW trial (2024) established nephroprotection3, and STEP-HFpEF trials (2023–2024) opened heart failure as a new indication6,9,12. The OASIS 1 trial validated oral semaglutide 50 mg for obesity11, and a 2025 NEJM publication established MASH as the latest indication10.

§07References